Cavalier Investments LLC Has $1.58 Million Position in Novo Nordisk A/S $NVO

Cavalier Investments LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 2.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 22,929 shares of the company’s stock after selling 460 shares during the quarter. Cavalier Investments LLC’s holdings in Novo Nordisk A/S were worth $1,583,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. raised its stake in Novo Nordisk A/S by 0.9% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 117,889 shares of the company’s stock valued at $8,137,000 after purchasing an additional 1,060 shares during the period. DecisionMap Wealth Management LLC raised its stake in Novo Nordisk A/S by 14.3% during the 2nd quarter. DecisionMap Wealth Management LLC now owns 8,418 shares of the company’s stock valued at $581,000 after purchasing an additional 1,052 shares during the period. Whittier Trust Co. of Nevada Inc. raised its stake in Novo Nordisk A/S by 3.2% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 81,517 shares of the company’s stock valued at $5,626,000 after purchasing an additional 2,533 shares during the period. Whittier Trust Co. raised its stake in Novo Nordisk A/S by 8.4% during the 2nd quarter. Whittier Trust Co. now owns 66,181 shares of the company’s stock valued at $4,568,000 after purchasing an additional 5,101 shares during the period. Finally, Lafayette Investments Inc. grew its holdings in shares of Novo Nordisk A/S by 579.4% during the 2nd quarter. Lafayette Investments Inc. now owns 47,754 shares of the company’s stock valued at $3,296,000 after acquiring an additional 40,725 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 1.7%

Shares of NYSE:NVO opened at $54.77 on Wednesday. The stock has a market capitalization of $244.55 billion, a PE ratio of 15.05, a P/E/G ratio of 2.53 and a beta of 0.68. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $116.65. The firm has a fifty day moving average price of $56.46 and a 200 day moving average price of $62.58. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio is 22.53%.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price target on the stock in a report on Wednesday, August 13th. Berenberg Bank upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Hsbc Global Res upgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 1st. Barclays restated an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Finally, Rothschild Redb upgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $76.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.